The evaluation of leukocytes in response to the in vitro testing of ventricular assist devices.

Infection is a clinically relevant adverse event in patients with ventricular assist device (VAD) support. The risk of infection could be linked to a reduced immune response resulting from damage to leukocytes during VAD support. The purpose of this study was to develop an understanding of leukocyte responses during the in vitro testing of VADs by analyzing the changes to their morphology and biochemistry. The VentrAssist implantable rotary blood pump (IRBP) and RotaFlow centrifugal pump (CP) were tested in vitro under constant hemodynamic conditions. Automated hematology analysis of samples collected regularly over 25-h tests was undertaken. A new flow cytometric assay was employed to measure biochemical alteration, necrosis (7-AAD) and morphological alteration (CD45 expression) of the circulating leukocytes during the pumping process. The results of hematology analysis show the total leukocyte number and subset counts decreased over the period of in vitro tests dependent on different blood pumps. The percentage of leukocytes damaged during 6-h tests was 40.8 ± 5.7% for the VentrAssist IRBP, 17.6 ± 5.4% for the RotaFlow CP, and 2.7 ± 1.8% for the static control (all n=5). Flow cytometric monitoring of CD45 expression and forward/side scatter characteristics revealed leukocytes that were fragmented into smaller pieces (microparticles). Scanning electron microscopy and imaging flow cytometry were used to confirm this. Device developers could use these robust cellular assays to gain a better understanding of leukocyte-specific VAD performance.

[1]  Bart Meyns,et al.  Mechanical stress activates platelets at a subhemolysis level: an in vitro study. , 2007, Artificial organs.

[2]  J. Loscalzo,et al.  Platelet-monocyte aggregates: bridging thrombosis and inflammation. , 2002, Circulation.

[3]  Ranjit John,et al.  Bleeding and Thrombosis in Patients With Continuous-Flow Ventricular Assist Devices , 2012, Circulation.

[4]  J. Hartwig,et al.  Extracellular DNA traps promote thrombosis , 2010, Proceedings of the National Academy of Sciences.

[5]  Stefan Fischer,et al.  Thrombus formation in a HeartMate II left ventricular assist device. , 2008, The Journal of thoracic and cardiovascular surgery.

[6]  R. Benza,et al.  Infection in ventricular assist devices: prevention and treatment. , 2003, The Annals of thoracic surgery.

[7]  Marvin A. Konstam,et al.  Emerging ventricular assist devices for long-term cardiac support , 2010, Nature Reviews Cardiology.

[8]  M. Shive,et al.  Shear stress-induced apoptosis of adherent neutrophils: a mechanism for persistence of cardiovascular device infections. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  E. Verrier,et al.  Systemic consequences of ventricular assist devices: alterations of coagulation, immune function, inflammation, and the neuroendocrine system. , 2002, Artificial organs.

[10]  Y Nosé,et al.  Design and development strategy for the rotary blood pump. , 1998, Artificial organs.

[11]  M. Slaughter,et al.  Acquired von Willebrand Syndrome in Patients With an Axial Flow Left Ventricular Assist Device , 2010, Circulation. Heart failure.

[12]  R. Paul,et al.  Shear stress related blood damage in laminar couette flow. , 2003, Artificial organs.

[13]  M. Slaughter,et al.  Blood trauma testing of CentriMag and RotaFlow centrifugal flow devices: a pilot study. , 2012, Artificial organs.

[14]  Kenji Yamazaki,et al.  Preclinical biocompatibility assessment of the EVAHEART ventricular assist device: coating comparison and platelet activation. , 2007, Journal of biomedical materials research. Part A.

[15]  Anna L Meyer,et al.  Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate II ventricular assist device. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[16]  K. Litwak,et al.  Platelet activation, aggregation, and life span in calves implanted with axial flow ventricular assist devices. , 2002, The Annals of thoracic surgery.

[17]  M. Olschewski,et al.  Enhanced microparticles in ventricular assist device patients predict platelet, leukocyte and endothelial cell activation. , 2010, Interactive cardiovascular and thoracic surgery.

[18]  L. Lorand,et al.  Structural origins of fibrin clot rheology. , 1999, Biophysical journal.

[19]  Natalie L James,et al.  Evaluation of hemolysis in the VentrAssist implantable rotary blood pump. , 2003, Artificial organs.

[20]  B. Hazarika.  What is missed in an automated cell count? , 2012, Blood.

[21]  A. Hilton,et al.  Reevaluation of the Harboe assay as a standardized method of assessment for the hemolytic performance of ventricular assist devices. , 2012, Artificial organs.

[22]  Kenji Yamazaki,et al.  Leukocyte-platelet aggregates and monocyte tissue factor expression in bovines implanted with ventricular assist devices. , 2007, Artificial organs.

[23]  A. Simon,et al.  Circulating Leukocyte-Derived Microparticles Predict Subclinical Atherosclerosis Burden in Asymptomatic Subjects , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[24]  H. ten Cate,et al.  From neutrophil extracellular traps release to thrombosis: an overshooting host‐defense mechanism? , 2011, Journal of thrombosis and haemostasis : JTH.

[25]  L. Nielsen,et al.  Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). , 2009, Journal of the American College of Cardiology.